comparemela.com

Page 13 - Shauna Dillon News Today : Breaking News, Live Updates & Top Stories | Vimarsana

ObsEva SA: ObsEva Announces Confirmation of Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland - April 25, 2022 - ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and

United statesShauna dillonSyneos healthorBrian ocallaghanEuropean commissionDrug administrationSwiss exchangeExchange commissionSyneos healthKissei pharmaceutical co ltdEuropean medicines agencyEuropean union member statesCommittee for medicinal products human useMedicinal productsHuman useMiddle east

ObsEva SA: ObsEva Annual General Meeting 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA - April 7, 2022 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing

United statesUnited kingdomPlan les ouatesWest islandCity ofAnnette clancyAnne vanlentFranciscus verwielBrian ocallaghanErnest loumayeStephanie brownShauna dillonEdward mathersCatarina edfjSanthera pharmaceuticalsCommittee for the fiscal year

ObsEva Annual General Meeting 2022

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA – April 7, 2022 – ObsEva SA (NASDAQ: OBSV /.

United statesUnited kingdomPlan les ouatesWest islandCity ofAnnette clancyAnne vanlentFranciscus verwielBrian ocallaghanErnest loumayeStephanie brownShauna dillonEdward mathersCatarina edfjSanthera pharmaceuticalsCommittee for the fiscal year

ObsEva SA: ObsEva Annual Report 2021

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland and Boston, MA - March 31, 2022 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company

United statesShauna dillonSwiss exchangeOffice contactAnnual reportNasdaq global select market

ObsEva SA: ObsEva Announces Additional Efficacy Results for Linzagolix 200 mg with Add-Back Therapy (ABT) and Linzagolix 75 mg without ABT in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain

-Reductions in dysmenorrhea (DYS) and non-menstrual pelvic pain (NMPP), the co-primary efficacy endpoints, compared to placebo were observed for both doses after 1 and 2 months of treatment, respectively

Shauna dillonHugh taylorExchange commissionYale universityEndometriosis health profileWorld endometriosis research foundationKissei pharmaceutical co ltdSwiss exchangeProgram in endometriosisChief medical officerNasdaq global select marketPrivate securities litigation reform actRisk factorsAnnual report

vimarsana © 2020. All Rights Reserved.